[{"id":"afc34dd5-440d-4768-b2d3-1f68bbdafbb1","acronym":"","url":"https://clinicaltrials.gov/study/NCT05470491","created_at":"2022-07-22T11:56:13.684Z","updated_at":"2025-02-25T13:54:33.177Z","phase":"Phase 1/2","brief_title":"Trial of Allogeneic Reduced-Intensity, HLA-Haploidentical Allogeneic Hematopoietic Cell Bone Marrow Transplantation Followed by Graft-versus-Host-Disease (GVHD) Prophylaxis With Cyclophosphamide, Bortezomib and Maraviroc for Hematologic Malignancies ...","source_id_and_acronym":"NCT05470491","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" IGH","pipe":"","alterations":" ","tags":["IGH"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e bortezomib • cyclophosphamide • Selzentry (maraviroc) • plerixafor"],"overall_status":"Recruiting","enrollment":" Enrollment 265","initiation":"Initiation: 01/26/2023","start_date":" 01/26/2023","primary_txt":" Primary completion: 07/30/2026","primary_completion_date":" 07/30/2026","study_txt":" Completion: 07/30/2027","study_completion_date":" 07/30/2027","last_update_posted":"2025-02-20"},{"id":"c6706368-4b51-4cd8-9e6f-57a4d3ecf646","acronym":"","url":"https://clinicaltrials.gov/study/NCT01526096","created_at":"2021-01-18T06:26:01.906Z","updated_at":"2025-02-25T16:43:39.104Z","phase":"Phase 1","brief_title":"Stem Cell Transplantation for Patients With Multiple Myeloma","source_id_and_acronym":"NCT01526096","lead_sponsor":"University of Chicago","biomarkers":" IL2RA • CD4 • FOXP3 • ISG20","pipe":"","alterations":" ","tags":["IL2RA • CD4 • FOXP3 • ISG20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e melphalan • plerixafor"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 15","initiation":"Initiation: 07/12/2011","start_date":" 07/12/2011","primary_txt":" Primary completion: 09/12/2025","primary_completion_date":" 09/12/2025","study_txt":" Completion: 09/12/2025","study_completion_date":" 09/12/2025","last_update_posted":"2025-02-05"},{"id":"e2c86e85-6b93-47fb-9960-a5caa4b6ea35","acronym":"MOZOBL06877","url":"https://clinicaltrials.gov/study/NCT03406091","created_at":"2021-01-18T16:48:18.086Z","updated_at":"2024-07-02T16:35:18.698Z","phase":"","brief_title":"Detection of Poor Mobilizer (PM) in Multiple Myeloma (MM) Patients","source_id_and_acronym":"NCT03406091 - MOZOBL06877","lead_sponsor":"Fondazione EMN Italy Onlus","biomarkers":" CD34","pipe":"","alterations":" ","tags":["CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e plerixafor"],"overall_status":"Completed","enrollment":" Enrollment 300","initiation":"Initiation: 11/26/2015","start_date":" 11/26/2015","primary_txt":" Primary completion: 01/19/2021","primary_completion_date":" 01/19/2021","study_txt":" Completion: 01/17/2024","study_completion_date":" 01/17/2024","last_update_posted":"2024-02-20"},{"id":"f9d51819-1dba-41df-bf66-31507a2e2587","acronym":"","url":"https://clinicaltrials.gov/study/NCT05088356","created_at":"2021-10-21T12:53:16.468Z","updated_at":"2024-07-02T16:35:18.982Z","phase":"Phase 1","brief_title":"Reduced Intensity Allogeneic HCT in Advanced Hematologic Malignancies w/T-Cell Depleted Graft","source_id_and_acronym":"NCT05088356","lead_sponsor":"Stanford University","biomarkers":" HLA-DRB1 • HLA-B • HLA-C","pipe":"","alterations":" ","tags":["HLA-DRB1 • HLA-B • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Jakafi (ruxolitinib) • cyclophosphamide • melphalan • fludarabine IV • thiotepa • Neupogen (filgrastim) • plerixafor"],"overall_status":"Recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 09/07/2021","start_date":" 09/07/2021","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2024-02-19"},{"id":"2d84d56d-dda0-4e45-bc47-da746b822f0d","acronym":"","url":"https://clinicaltrials.gov/study/NCT01696461","created_at":"2021-01-18T07:22:14.622Z","updated_at":"2024-07-02T16:35:36.969Z","phase":"Phase 2","brief_title":"A Phase II Study Evaluating the Safety and Efficacy of Subcutaneous Plerixafor","source_id_and_acronym":"NCT01696461","lead_sponsor":"Center for International Blood and Marrow Transplant Research","biomarkers":" CD33 • CD34","pipe":"","alterations":" ","tags":["CD33 • CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • plerixafor"],"overall_status":"Completed","enrollment":" Enrollment 127","initiation":"Initiation: 05/01/2013","start_date":" 05/01/2013","primary_txt":" Primary completion: 08/01/2016","primary_completion_date":" 08/01/2016","study_txt":" Completion: 08/01/2016","study_completion_date":" 08/01/2016","last_update_posted":"2023-09-14"},{"id":"c39bcb1d-4ab0-4b6b-b2bd-56001aac7f38","acronym":"","url":"https://clinicaltrials.gov/study/NCT05510544","created_at":"2022-08-22T13:04:22.282Z","updated_at":"2024-07-02T16:35:53.476Z","phase":"Phase 4","brief_title":"Plerixafor for Poorly Mobilized Lymphoma","source_id_and_acronym":"NCT05510544","lead_sponsor":"Peking University","biomarkers":" CD34","pipe":"","alterations":" ","tags":["CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e plerixafor"],"overall_status":"Recruiting","enrollment":" Enrollment 140","initiation":"Initiation: 12/19/2022","start_date":" 12/19/2022","primary_txt":" Primary completion: 12/20/2023","primary_completion_date":" 12/20/2023","study_txt":" Completion: 01/31/2024","study_completion_date":" 01/31/2024","last_update_posted":"2023-03-13"},{"id":"6db5c3f8-e3ab-4a02-ac01-26e44b4d72e7","acronym":"","url":"https://clinicaltrials.gov/study/NCT05007652","created_at":"2021-08-16T16:54:47.451Z","updated_at":"2024-07-02T16:35:55.110Z","phase":"Phase 2","brief_title":"A Study of KRN125 in Patients With Multiple Myeloma and Malignant Lymphoma","source_id_and_acronym":"NCT05007652","lead_sponsor":"Kyowa Kirin Co., Ltd.","biomarkers":" CD34","pipe":"","alterations":" ","tags":["CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Neulasta (pegfilgrastim) • Neupogen (filgrastim) • plerixafor"],"overall_status":"Completed","enrollment":" Enrollment 64","initiation":"Initiation: 09/01/2021","start_date":" 09/01/2021","primary_txt":" Primary completion: 10/25/2022","primary_completion_date":" 10/25/2022","study_txt":" Completion: 10/25/2022","study_completion_date":" 10/25/2022","last_update_posted":"2023-02-21"},{"id":"5e54474b-d2cf-495a-a3c2-dafc873e6e05","acronym":"","url":"https://clinicaltrials.gov/study/NCT05087212","created_at":"2021-10-21T12:53:04.089Z","updated_at":"2024-07-02T16:35:56.705Z","phase":"Phase 4","brief_title":"Mobilization of Stem Cells With AMD3100 (Plerixafor) in Combination With G-CSF in Multiple Myeloma Patients","source_id_and_acronym":"NCT05087212","lead_sponsor":"Sanofi","biomarkers":" CD34","pipe":"","alterations":" ","tags":["CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e plerixafor"],"overall_status":"Completed","enrollment":" Enrollment 53","initiation":"Initiation: 10/22/2021","start_date":" 10/22/2021","primary_txt":" Primary completion: 12/06/2022","primary_completion_date":" 12/06/2022","study_txt":" Completion: 12/30/2022","study_completion_date":" 12/30/2022","last_update_posted":"2023-01-31"},{"id":"100d53c1-a871-4c02-b038-7972188d3735","acronym":"","url":"https://clinicaltrials.gov/study/NCT03317899","created_at":"2021-01-18T16:23:07.420Z","updated_at":"2024-07-02T16:36:00.230Z","phase":"Phase 2","brief_title":"Stem Cell Transplant With or Without Tbo-filgrastim in Treating Patients With Multiple Myeloma or Non-Hodgkin Lymphoma","source_id_and_acronym":"NCT03317899","lead_sponsor":"Sidney Kimmel Cancer Center at Thomas Jefferson University","biomarkers":" CD34","pipe":"","alterations":" ","tags":["CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Neupogen (filgrastim) • plerixafor"],"overall_status":"Completed","enrollment":" Enrollment 76","initiation":"Initiation: 10/12/2017","start_date":" 10/12/2017","primary_txt":" Primary completion: 06/01/2021","primary_completion_date":" 06/01/2021","study_txt":" Completion: 11/16/2022","study_completion_date":" 11/16/2022","last_update_posted":"2022-11-17"},{"id":"ea8cd680-2cf6-43af-ad88-79a19110de77","acronym":"IRB-57056","url":"https://clinicaltrials.gov/study/NCT04552743","created_at":"2021-01-18T21:46:04.906Z","updated_at":"2024-07-02T16:36:04.116Z","phase":"Phase 2","brief_title":"MGTA-145 + Plerixafor in the Mobilization of Hematopoietic Stem Cells for Autologous Transplantation in Multiple Myeloma","source_id_and_acronym":"NCT04552743 - IRB-57056","lead_sponsor":"Surbhi Sidana, MD","biomarkers":" CD34","pipe":"","alterations":" ","tags":["CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MGTA-145 • plerixafor"],"overall_status":"Completed","enrollment":" Enrollment 25","initiation":"Initiation: 10/05/2020","start_date":" 10/05/2020","primary_txt":" Primary completion: 07/22/2021","primary_completion_date":" 07/22/2021","study_txt":" Completion: 06/30/2022","study_completion_date":" 06/30/2022","last_update_posted":"2022-09-12"},{"id":"26dcd2fa-ec50-459b-9b24-a5633f4a1586","acronym":"","url":"https://clinicaltrials.gov/study/NCT02703779","created_at":"2021-01-18T13:12:05.048Z","updated_at":"2024-07-02T16:36:28.932Z","phase":"Phase 2","brief_title":"Exploratory Trial to Estimate Proportion of Patients With Tumor Cell Contaminated Leukapheresis Products With and Without Bortezomib With In-vivo Purging - Multiple Myeloma (MM)","source_id_and_acronym":"NCT02703779","lead_sponsor":"Siddhartha Ganguly","biomarkers":" CD34","pipe":" | ","alterations":" CD34 positive","tags":["CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD34 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e bortezomib • Neupogen (filgrastim) • plerixafor"],"overall_status":"Completed","enrollment":" Enrollment 101","initiation":"Initiation: 03/01/2016","start_date":" 03/01/2016","primary_txt":" Primary completion: 10/04/2019","primary_completion_date":" 10/04/2019","study_txt":" Completion: 04/08/2020","study_completion_date":" 04/08/2020","last_update_posted":"2021-06-18"},{"id":"78a08048-158a-4be0-94e8-5e7757b32c7c","acronym":"","url":"https://clinicaltrials.gov/study/NCT01753453","created_at":"2021-01-18T07:41:53.252Z","updated_at":"2024-07-02T16:36:34.223Z","phase":"Phase 2","brief_title":"An Exploratory Safety Study to Investigate the Extent of Tumor Cell Mobilization (TCM) After Use of G-CSF Alone or G-CSF Plus Plerixafor in Multiple Myeloma (MM) Patients Who May be Poor Mobilizers of Stem Cells","source_id_and_acronym":"NCT01753453","lead_sponsor":"Sanofi","biomarkers":" CD34","pipe":"","alterations":" ","tags":["CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e plerixafor"],"overall_status":"Completed","enrollment":" Enrollment 23","initiation":"Initiation: 06/01/2013","start_date":" 06/01/2013","primary_txt":" Primary completion: 09/01/2016","primary_completion_date":" 09/01/2016","study_txt":" Completion: 09/01/2016","study_completion_date":" 09/01/2016","last_update_posted":"2021-02-23"},{"id":"ebdeb635-d206-4c76-a258-53dd95830adc","acronym":"IFM-2015-03","url":"https://clinicaltrials.gov/study/NCT02439476","created_at":"2021-01-18T11:41:09.380Z","updated_at":"2024-07-02T16:36:35.885Z","phase":"","brief_title":"Non-interventional Study on Salvage Auto in Relapsed Myeloma","source_id_and_acronym":"NCT02439476 - IFM-2015-03","lead_sponsor":"Association for Training, Education, and Research in Hematology, Immunology, and Transplantation","biomarkers":" CD34","pipe":"","alterations":" ","tags":["CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e melphalan • plerixafor"],"overall_status":"Completed","enrollment":" Enrollment 23","initiation":"Initiation: 08/08/2016","start_date":" 08/08/2016","primary_txt":" Primary completion: 08/08/2020","primary_completion_date":" 08/08/2020","study_txt":" Completion: 08/08/2020","study_completion_date":" 08/08/2020","last_update_posted":"2021-01-20"},{"id":"20ea16e5-536b-44a1-a781-e41dbdf77160","acronym":"NYSCT MM","url":"https://clinicaltrials.gov/study/NCT03506802","created_at":"2021-01-19T15:52:47.043Z","updated_at":"2025-02-25T15:43:03.287Z","phase":"Phase 1","brief_title":"TCR Genetically Engineered PBMC and PBSC After Melphalan Conditioning Regimen in Treating Participants With Relapsed and Refractory Multiple Myeloma","source_id_and_acronym":"NCT03506802 - NYSCT MM","lead_sponsor":"Jonsson Comprehensive Cancer Center","biomarkers":" CTAG1B","pipe":"","alterations":" ","tags":["CTAG1B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lenalidomide • melphalan • Proleukin (aldesleukin) • Neupogen (filgrastim) • plerixafor"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 07/10/2018","start_date":" 07/10/2018","primary_txt":" Primary completion: 06/25/2019","primary_completion_date":" 06/25/2019","study_txt":" Completion: 06/25/2019","study_completion_date":" 06/25/2019","last_update_posted":"2020-07-24"},{"id":"2731c2e0-e0ee-407b-991d-a26610597271","acronym":"","url":"https://clinicaltrials.gov/study/NCT01146834","created_at":"2021-01-18T04:33:50.720Z","updated_at":"2025-02-25T14:55:56.560Z","phase":"Phase 3","brief_title":"Trial of Three Stem Cell Mobilization Regimens for Multiple Myeloma","source_id_and_acronym":"NCT01146834","lead_sponsor":"Weill Medical College of Cornell University","biomarkers":" CD34","pipe":"","alterations":" ","tags":["CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e bortezomib • cyclophosphamide • Neupogen (filgrastim) • cyclophosphamide intravenous • plerixafor"],"overall_status":"Completed","enrollment":" Enrollment 47","initiation":"Initiation: 03/01/2011","start_date":" 03/01/2011","primary_txt":" Primary completion: 02/04/2019","primary_completion_date":" 02/04/2019","study_txt":" Completion: 02/04/2019","study_completion_date":" 02/04/2019","last_update_posted":"2019-12-27"},{"id":"039b01a5-289c-432a-8db6-4ba36c0d53c7","acronym":"","url":"https://clinicaltrials.gov/study/NCT02343666","created_at":"2021-01-18T11:08:26.454Z","updated_at":"2024-07-02T16:37:05.148Z","phase":"Phase 1","brief_title":"HIV-Resistant Gene Modified Stem Cells and Chemotherapy in Treating Patients With Lymphoma With HIV Infection","source_id_and_acronym":"NCT02343666","lead_sponsor":"Fred Hutchinson Cancer Center","biomarkers":" CD34 • CD4","pipe":"","alterations":" ","tags":["CD34 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carmustine • Neupogen (filgrastim) • plerixafor"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 08/15/2016","start_date":" 08/15/2016","primary_txt":" Primary completion: 08/01/2020","primary_completion_date":" 08/01/2020","study_txt":"","study_completion_date":"","last_update_posted":"2018-11-20"},{"id":"5196c7bf-5bf9-4cf9-8711-f852ccafb593","acronym":"","url":"https://clinicaltrials.gov/study/NCT01319864","created_at":"2021-01-18T05:22:22.912Z","updated_at":"2024-07-02T16:37:07.140Z","phase":"Phase 1","brief_title":"POETIC Plerixafor as a Chemosensitizing Agent for Relapsed Acute Leukemia and MDS in Pediatric Patients","source_id_and_acronym":"NCT01319864","lead_sponsor":"Seattle Children's Hospital","biomarkers":" CXCR4","pipe":" | ","alterations":" CXCR4 expression","tags":["CXCR4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CXCR4 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • plerixafor"],"overall_status":"Completed","enrollment":" Enrollment 20","initiation":"Initiation: 03/01/2011","start_date":" 03/01/2011","primary_txt":" Primary completion: 06/28/2013","primary_completion_date":" 06/28/2013","study_txt":" Completion: 06/28/2016","study_completion_date":" 06/28/2016","last_update_posted":"2018-09-07"},{"id":"ab864958-399d-451e-b668-5eba2ff86a0a","acronym":"","url":"https://clinicaltrials.gov/study/NCT01352650","created_at":"2021-01-18T05:31:47.169Z","updated_at":"2024-07-02T16:37:09.315Z","phase":"Phase 1","brief_title":"Decitabine and Plerixafor in Elderly Acute Myeloid Leukemia (AML)","source_id_and_acronym":"NCT01352650","lead_sponsor":"Weill Medical College of Cornell University","biomarkers":" RUNX1 • PML","pipe":"","alterations":" ","tags":["RUNX1 • PML"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e decitabine • plerixafor"],"overall_status":"Completed","enrollment":" Enrollment 71","initiation":"Initiation: 06/17/2011","start_date":" 06/17/2011","primary_txt":" Primary completion: 12/27/2016","primary_completion_date":" 12/27/2016","study_txt":" Completion: 12/27/2016","study_completion_date":" 12/27/2016","last_update_posted":"2018-07-02"},{"id":"ba4fa3b5-ae9d-472a-b5bd-ea1ff624760e","acronym":"","url":"https://clinicaltrials.gov/study/NCT01547806","created_at":"2021-01-18T06:32:46.878Z","updated_at":"2024-07-02T16:37:13.252Z","phase":"Phase 2","brief_title":"Collection of Transplant Stem Cells for Plasma Cell Myeloma","source_id_and_acronym":"NCT01547806","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD34","pipe":"","alterations":" ","tags":["CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Neupogen (filgrastim) • plerixafor"],"overall_status":"Completed","enrollment":" Enrollment 49","initiation":"Initiation: 02/22/2012","start_date":" 02/22/2012","primary_txt":" Primary completion: 06/17/2014","primary_completion_date":" 06/17/2014","study_txt":" Completion: 01/11/2018","study_completion_date":" 01/11/2018","last_update_posted":"2018-03-07"},{"id":"3e4af630-5de2-4899-a36c-a483964ed3b7","acronym":"","url":"https://clinicaltrials.gov/study/NCT01097057","created_at":"2021-01-18T04:20:16.620Z","updated_at":"2024-07-02T16:37:14.563Z","phase":"Phase 2","brief_title":"Rituximab, Combination Chemotherapy, Filgrastim (G-CSF), and Plerixafor in Treating Patients With Non-Hodgkin Lymphoma Undergoing Mobilization of Autologous Peripheral Blood Stem Cells","source_id_and_acronym":"NCT01097057","lead_sponsor":"Fred Hutchinson Cancer Center","biomarkers":" CD20 • CD34","pipe":"","alterations":" ","tags":["CD20 • CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • Rituxan (rituximab) • cyclophosphamide • ifosfamide • etoposide IV • Neupogen (filgrastim) • Novex (rituximab biosimilar) • cyclophosphamide intravenous • plerixafor"],"overall_status":"Completed","enrollment":" Enrollment 20","initiation":"Initiation: 11/09/2010","start_date":" 11/09/2010","primary_txt":" Primary completion: 09/01/2013","primary_completion_date":" 09/01/2013","study_txt":" Completion: 12/26/2017","study_completion_date":" 12/26/2017","last_update_posted":"2018-01-23"},{"id":"921493cc-b8ac-40af-96ea-93fe788c7c08","acronym":"","url":"https://clinicaltrials.gov/study/NCT03244930","created_at":"2021-01-18T16:02:02.562Z","updated_at":"2024-07-02T16:37:19.034Z","phase":"Phase 2","brief_title":"Low Dose Plerixafor Plus G-CSF in Mobilizing Stem Cells for Autologous Peripheral Blood Transplantation","source_id_and_acronym":"NCT03244930","lead_sponsor":"Hospital Universitario Dr. Jose E. Gonzalez","biomarkers":" CD34","pipe":"","alterations":" ","tags":["CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e plerixafor"],"overall_status":"Unknown status","enrollment":" Enrollment 20","initiation":"Initiation: 05/10/2017","start_date":" 05/10/2017","primary_txt":" Primary completion: 05/10/2018","primary_completion_date":" 05/10/2018","study_txt":" Completion: 06/10/2018","study_completion_date":" 06/10/2018","last_update_posted":"2017-08-10"},{"id":"fce12c01-98e0-4615-8d90-a581622ebfad","acronym":"","url":"https://clinicaltrials.gov/study/NCT01403896","created_at":"2021-01-18T05:46:07.166Z","updated_at":"2024-07-02T16:37:19.204Z","phase":"Phase 2","brief_title":"Healthy Donor Study II - Comparing Plerixafor With G-CSF and Plerixafor","source_id_and_acronym":"NCT01403896","lead_sponsor":"Stephen Couban","biomarkers":" CD34 • CD4 • CD27 • TLR9","pipe":"","alterations":" ","tags":["CD34 • CD4 • CD27 • TLR9"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Neupogen (filgrastim) • plerixafor"],"overall_status":"Completed","enrollment":" Enrollment 10","initiation":"Initiation: 04/01/2012","start_date":" 04/01/2012","primary_txt":" Primary completion: 12/01/2015","primary_completion_date":" 12/01/2015","study_txt":" Completion: 12/01/2015","study_completion_date":" 12/01/2015","last_update_posted":"2017-08-02"},{"id":"9d4ce128-8bf7-4a96-a261-efb5393d3c4e","acronym":"","url":"https://clinicaltrials.gov/study/NCT01339572","created_at":"2021-01-18T05:27:56.123Z","updated_at":"2024-07-02T16:37:19.321Z","phase":"Phase 2","brief_title":"Clinical And Economic Impact Of Upfront Plerixafor In Autologous Transplantation","source_id_and_acronym":"NCT01339572","lead_sponsor":"University of Florida","biomarkers":" CD34","pipe":"","alterations":" ","tags":["CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Neupogen (filgrastim) • plerixafor"],"overall_status":"Completed","enrollment":" Enrollment 72","initiation":"Initiation: 04/01/2011","start_date":" 04/01/2011","primary_txt":" Primary completion: 11/01/2015","primary_completion_date":" 11/01/2015","study_txt":" Completion: 11/01/2015","study_completion_date":" 11/01/2015","last_update_posted":"2017-08-01"},{"id":"0b516e08-7e9f-4b9a-b085-abe38da396c0","acronym":"","url":"https://clinicaltrials.gov/study/NCT02098109","created_at":"2021-01-18T09:41:14.579Z","updated_at":"2024-07-02T16:37:19.802Z","phase":"Phase 2","brief_title":"Non-inferiority Study of XM02 Filgrastim (Granix) and Filgrastim (Neupogen) in Combination With Plerixafor for Autologous Stem Cell Mobilization in Patients With Multiple Myeloma or Non-Hodgkin Lymphoma","source_id_and_acronym":"NCT02098109","lead_sponsor":"Washington University School of Medicine","biomarkers":" CD34","pipe":"","alterations":" ","tags":["CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Neulasta (pegfilgrastim) • plerixafor"],"overall_status":"Completed","enrollment":" Enrollment 100","initiation":"Initiation: 08/20/2014","start_date":" 08/20/2014","primary_txt":" Primary completion: 06/10/2016","primary_completion_date":" 06/10/2016","study_txt":" Completion: 09/18/2016","study_completion_date":" 09/18/2016","last_update_posted":"2017-07-18"}]